Imperial College London
Portrait Picture

Professor Omar Usmani

Faculty of Medicine, National Heart & Lung Institute

Professor of Respiratory Medicine
 
 
 
//

Contact

 

+44 (0)20 7351 8051o.usmani

 
 
//

Location

 

Asthma LabSouth BlockRoyal Brompton Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Dreher:2021:10.1177/1479973120986228,
author = {Dreher, M and Price, D and Gardev, A and Peeters, P and Arora, S and van, der Sar-van der Brugge S and Dekhuijzen, R and Usmani, OS},
doi = {10.1177/1479973120986228},
journal = {Chronic Respiratory Disease},
pages = {1--10},
title = {Patient perceptions of the re-usable Respimatt(R) Soft Mist (TM) inhaler in current users and those switching to the device: A real-world, non-interventional COPD study},
url = {http://dx.doi.org/10.1177/1479973120986228},
volume = {18},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - The Respimat® Soft Mist™ inhaler (SMI) has recently been improved, with a re-usable device replacing the disposable version. Certain countries are currently phasing out the disposable inhaler. This study aimed to assess patient satisfaction with and preference for the re-usable device. This 4–6-week, multicentre, open-label, prospective, real-world, non-interventional study was conducted across six European countries. Patients with chronic obstructive pulmonary disease were enrolled between October and December 2019, in three cohorts: (1) currently using the re-usable Respimat SMI; (2) switched from disposable Respimat SMI at study entry; and (3) naïve to any Respimat SMI. Patients were assessed using the Patient Satisfaction and Preference Questionnaire (PASAPQ) and Ease of Handling Questionnaire. In total, 262 patients were enrolled. At follow-up, the mean PASAPQ score was 83.3/100 overall, with similar results across all three patient cohorts. Most patients were ‘satisfied’ or ‘very satisfied’ with the re-usable device. The overall score for willingness to continue using the device was 87.8/100. In total, 13 adverse events were recorded, none of which was classified as serious. This study provides real-world evidence for practitioners to start patients on Respimat re-usable, irrespective of a patient’s prior experience with this inhaler.
AU  - Dreher,M
AU  - Price,D
AU  - Gardev,A
AU  - Peeters,P
AU  - Arora,S
AU  - van,der Sar-van der Brugge S
AU  - Dekhuijzen,R
AU  - Usmani,OS
DO  - 10.1177/1479973120986228
EP  - 10
PY  - 2021///
SN  - 1479-9723
SP  - 1
TI  - Patient perceptions of the re-usable Respimatt(R) Soft Mist (TM) inhaler in current users and those switching to the device: A real-world, non-interventional COPD study
T2  - Chronic Respiratory Disease
UR  - http://dx.doi.org/10.1177/1479973120986228
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000617444700001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - https://journals.sagepub.com/doi/10.1177/1479973120986228
UR  - http://hdl.handle.net/10044/1/87052
VL  - 18
ER  -
Download